PSN 602

Drug Profile

PSN 602

Alternative Names: PSN602

Latest Information Update: 07 Jul 2010

Price : $50

At a glance

  • Originator Prosidion
  • Class Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 31 Dec 2009 Discontinued - Phase-I for Obesity in United Kingdom (PO)
  • 12 May 2009 Efficacy and adverse events data from a phase I trial in obesity released by OSI Pharmaceuticals
  • 19 Jun 2008 Phase-I clinical trials in Obesity in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top